Antibiotic Nanopartikel menyerang infeksi pernapasan pada sumber , mengurangi efek samping obat--T-REC-komunitas reptil-semarang--KSE-komunitas satwa eksotik

SILAHKAN MENGGUNAKAN " MESIN TRANSLATE "..GOOGLE TRANSLATE
DISAMPING KANAN INI.............

PLEASE USE ........ "TRANSLATE MACHINE" .. GOOGLE TRANSLATE BESIDE RIGHT THIS

.................


T-REC -TUGUMUDA REPTILES COMMUNITY-INDONESIA


More info :
www.trecsemarang2011.blogspot.com
minat gabung : ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
08995557626
..................................
KSE – KOMUNITAS SATWA EKSOTIK – EXOTIC PETS COMMUNITY-- INDONESIA
Visit Our Community and Joint W/ Us....Welcome All Over The World
www.facebook.com/groups/komunitassatwaeksotik/
 KSE = KOMUNITAS SATWA EKSOTIK

MENGATASI KENDALA MINAT DAN JARAK

KAMI ADA DI TIAP KOTA DI INDONESIA
DETAIL TENTANG KSE-----KLIK : www.komunitassatwaeksotik-pendaftaran.blogspot.com

GABUNG......... ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
HUBUNGI   :  089617123865

.........................

Antibiotic Nanopartikel  menyerang infeksi pernapasan pada sumber , mengurangi efek samping obat

Mengobati penyakit pernapasan seringkali sulit karena obat harus melintasi hambatan biologis seperti jaringan pernapasan dan mukosa , dan karena itu harus diberikan dalam jumlah besar agar jumlah yang efektif mencapai target . Sekarang para peneliti telah menunjukkan bahwa penggunaan nanopartikel untuk membawa antibiotik di seluruh hambatan biologis dapat efektif dalam mengobati infeksi paru-paru . memungkinkan pengiriman yang lebih baik dari obat ke tempat infeksi , dan karenanya mencegah perkembangan resistensi antibiotik yang dapat disebabkan oleh dosis terlalu besar dan  antibiotik  yang kontinu . Selain itu , strategi tersebut mungkin membantu untuk mengatasi metabolisme yang cepat dan ekskresi antibiotik dari tubuh, yang terjadi ketika dikelola oleh rute tradisional , baik secara lisan atau intravena ......read more

Antibiotic
nanoparticles attack respiratory infection at source, reduce drug side effects

Date:

March 12, 2015

Source:

European Respiratory
Society (ERS)

Summary:

Treating respiratory
disease is often difficult because drugs have to cross biological barriers such
as respiratory tissue and mucosa, and must therefore be given in large
quantities in order for an effective amount to reach the target. Now
researchers have shown that the use of nanoparticles to carry antibiotics
across biological barriers can be effective in treating lung infections. Doing
so allows better delivery of the drug to the site of infection, and hence
prevents the development of antibiotic resistance which may be caused by too
large and continued doses of antibiotic. Additionally, such a strategy might
help to overcome the rapid metabolism and excretion of the antibiotic from the
body, which happens when it is administered by traditional routes, either
orally or intravenously.

......................

treating respiratory
disease is often difficult because drugs have to cross biological barriers such
as respiratory tissue and mucosa, and must therefore be given in large
quantities in order for an effective amount to reach the target. Now
researchers from Germany, Brazil and France have shown that the use of
nanoparticles to carry antibiotics across biological barriers can be effective
in treating lung infections. Doing so allows better delivery of the drug to the
site of infection, and hence prevents the development of antibiotic resistance
which may be caused by too large and continued doses of antibiotic.
Additionally, such a strategy might help to overcome the rapid metabolism and
excretion of the antibiotic from the body, which happens when it is administered
by traditional routes, either orally or intravenously.

Describing her team's work to the 13th European Respiratory Society Lung
Science Conference in Estoril, Dr Cristiane Carvalho-Wodarz, from the Helmholtz
Institute for Pharmaceutical Research, Saarbrücken, Germany, will say that, by
developing nanoparticles loaded with clarithromycin, an antibiotic commonly
used in the treatment of respiratory infections, they have been able to mimick
the process that occurs after inhalation in vivo by delivering the drug through
aerosol deposition to lung cells. Nanoparticles, which are in the same size
range as a virus -- millions of times smaller than a tennis ball -- were
prepared by adding a biodegradable polymer oil, stabiliser and clarithromycin
dissolved in solvents, to an aqueous surfactant solution. Subsequently, the
solvents were completely removed. "The delivery of nanoparticles in this
way enables their deposition in cells cultivated in vitro in a similar way to
the deposition in vivo, which take place in the alveoli (air sacs found in the
respiratory tract)," Dr Carvalho-Wodarz will say.

The researchers used the bacterium Staphylococcus aureus as the model for
their experiment, since it is one of the major causes of hospital-acquired
infection and also plays a crucial role in the lung infections which are common
in the genetic disorder cystic fibrosis. The tiny clarithromycin nanoparticles
(CLARI-NPs), were able to access the bacteria located either in biofilms (cells
sticking to each other on a surface) or inside individual lung cells.
"Neither of these locations is conducive to effective drug delivery
through traditional routes," says Dr Carvalho-Wodarz, "so we were
pleased to see that not only did the use of CLARI-NPs allow the uptake of the
antibiotic by the lung cells, but also that there were no toxic effects on all
the cell types on which we tested."

To date the work has been in vitro, using human bronchial cells. The
researchers now hope to evaluate its effectiveness in an animal model, probably
mice. They would also like to test the same nanoparticles loaded with other
drugs used against lung infections, and in particular those in which the
infectious agent becomes drug-resistant after the continued large doses that
may be required.

"Using nanoparticles to deliver drugs to a local site of infection is
a promising strategy for overcoming side effects, increasing treatment
efficacy, and overcoming resistance. The nanoparticles we have developed have a
number of advantages as drug carriers; they do not provoke a toxic effect, they
are highly stable, they release the drug over a sustained period, and they can
overcome cellular barriers. We believe that our formulation shows promise to
improve the antibacterial efficacy which could help patients with lung infections,
since the antibiotic can reach the infection site directly and therefore
decrease the side effects we see during traditional routes of
administration," Dr Carvalho-Wodarz will conclude.







Story Source:

The above story is based on materials provided by European Respiratory Society (ERS). Note: Materials may be edited
for content and length.




http://www.sciencedaily.com/releases/2015/03/150312202134.htm

Share this: